DAL-GenE Phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular risk in a genetically defined population with a recent acute coronary syndrome. The Dal-GenE clinical…
Publications
2022 Study of effect modifiers of genetically predicted CETP reduction. Legault M-A, Barhdadi A, Gamache I, Lemacon A, Lemieux Perreault L-P, Grenier J-C, Sylvestre M-P, Hussin JG, Rhainds D, Tardif…